A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex<sup>®</sup>), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
Alena Novotná(Nemocnice Pardubického Kraje), Jan Mareš, A Klimek, Zdeněk Ambler(University Hospital Plzen), Claudio Gasperini(Nini Hospital), Luca Ausili Cefaro(Azienda Ospedaliera Sant'Andrea), Olga Zapletalová, Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Paul Davies(Northampton General Hospital), Marta Vachová(Regional Museum in Teplice), Z Stelmasiak(Instytut Medycyny Wsi im. Witolda Chodźki), Carlo Pozzilli(Ophthalmology Clinic), Paolo Rossi(Associazione Italiana Sclerosi Multipla), S. Ratcliffe(Motac Neuroscience (United Kingdom)), Giancarlo Comi(Vita-Salute San Raffaele University), Alf-Peter Erdmann(Peterborough City Hospital), Iveta Nováková
Cited by 465
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k